Drug
Biib122
Biib122: highest development phase Phase 3, developed by Biogen, Denali Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Biogen, Denali Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| BIIB122 NCT05418673 | Phase 3 | Parkinson Disease |
| BIIB122 NCT05348785 | Phase 2 | Parkinson Disease |
| BIIB122 225 mg NCT06602193 | Phase 2 | Parkinson Disease |
| BIIB122 (DNL151) NCT05005338 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Biib122 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.